Sterling Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Sterling Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.8K	Buy	1,387 +1,138	+457%	+$28.5K	﹤0.01%	2071
2026 Q2	$7.39K	Sell	249 -751	-75%	-$16.8K	﹤0.01%	2391
2026 Q1	$19.9K	Sell	1,000 -720	-42%	-$12.4K	﹤0.01%	2031
2025 Q4	$28.9K	Sell	1,720 -506	-23%	-$8.64K	﹤0.01%	2032
2025 Q3	$35.1K	Buy	2,226 +1,352	+155%	+$15.1K	﹤0.01%	1892
2025 Q2	$8.12K	Buy	874 +712	+440%	+$8.49K	﹤0.01%	2260
2025 Q1	$2.11K	Sell	162 -114	-41%	-$1.51K	﹤0.01%	2574
2024 Q4	$4.81K	Buy	+276	New	+$5.74K	﹤0.01%	2480

Other funds holding BCAX

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sterling Capital Management's BCAX Position: Q3 2026 in Review

Sterling Capital Management increased its Bicara Therapeutics (BCAX) stake by 457% in Q3 2026, buying an estimated $28.5K and bringing the position to 1,387 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Sterling Capital Management first reported a position in BCAX in Q4 2024 and has held it in 8 quarters since. The position peaked at $35.1K in Q3 2025. 13 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

Sterling Capital Management held 1,387 shares of Bicara Therapeutics worth $25.8K as of Q3 2026.
Sterling Capital Management bought 1,138 Bicara Therapeutics shares in Q3 2026, an estimated $28.5K.
Bicara Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2071 holding.
Sterling Capital Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 8 quarters since.
Sterling Capital Management's Bicara Therapeutics position peaked at $35.1K in Q3 2025.
13 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.